Literature DB >> 9507095

Stoichiometry and heterogeneity of the pro-region chain in tetrameric human cathepsin C.

B Cigić1, I Krizaj, B Kralj, V Turk, R H Pain.   

Abstract

The subunit structure and composition of mature human cathepsin C, an oligomeric cysteine proteinase, has been characterised in detail. The heavy chain, light chain and pro-region peptides are shown to be held together solely by non-covalent interactions, and to be present in equimolar ratio, suggesting an important structural role for the residual pro-region chain which is strongly bound to the enzyme. The mass of the light chain, as determined by mass spectrometry, combined with its N-terminal sequence, determines the position of cleavage from the heavy chain. Amino-acid sequencing has led to definition of the 13.5 kDa N-terminal part of the pro-region which remains in the mature enzyme, the C-terminal moiety of 10 kDa being cleaved out and lost from the pro-peptide on activation. The residual pro-region is heterogeneous, a proportion being intact and the remainder being cleaved at alternative positions 58 or 61, yielding two smaller peptides joined by disulphide bond. The proportion of cleaved form was found to vary with tissue and enzyme preparation but did not affect enzyme activity. The molecular masses of the constituent chains after deglycosylation lead to a protein mass of 158 kDa. All four potential glycosylation sites are glycosylated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9507095     DOI: 10.1016/s0167-4838(97)00173-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  S2' substrate specificity and the role of His110 and His111 in the exopeptidase activity of human cathepsin B.

Authors:  Joanne C Krupa; Sadiq Hasnain; Dorit K Nägler; Robert Ménard; John S Mort
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

2.  Identification of cathepsin C mutations in ethnically diverse papillon-Lefèvre syndrome patients.

Authors:  P S Hart; Y Zhang; E Firatli; C Uygur; M Lotfazar; M D Michalec; J J Marks; X Lu; B J Coates; W K Seow; R Marshall; D Williams; J B Reed; J T Wright; T C Hart
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

3.  Free-thiol Cys331 exposed during activation process is critical for native tetramer structure of cathepsin C (dipeptidyl peptidase I).

Authors:  Martin Horn; Miroslav Baudys; Zdenek Voburka; Ivan Kluh; Jirí Vondrásek; Michael Mares
Journal:  Protein Sci       Date:  2002-04       Impact factor: 6.725

4.  Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases.

Authors:  D Turk; V Janjić; I Stern; M Podobnik; D Lamba; S W Dahl; C Lauritzen; J Pedersen; V Turk; B Turk
Journal:  EMBO J       Date:  2001-12-03       Impact factor: 11.598

5.  Biochemical characterization of Plasmodium falciparum dipeptidyl aminopeptidase 1.

Authors:  Flora Wang; Priscilla Krai; Edgar Deu; Brittney Bibb; Conni Lauritzen; John Pedersen; Matthew Bogyo; Michael Klemba
Journal:  Mol Biochem Parasitol       Date:  2010-09-15       Impact factor: 1.759

6.  Expression and purification of active recombinant cathepsin C (dipeptidyl aminopeptidase I) of kuruma prawn Marsupenaeus japonicus in insect cells.

Authors:  Gao-Feng Qiu; Hai-Yang Feng; Keisuke Yamano
Journal:  J Biomed Biotechnol       Date:  2009-08-18

7.  Regulation of split anergy in natural killer cells by inhibition of cathepsins C and H and cystatin F.

Authors:  Špela Magister; Han-Ching Tseng; Vickie T Bui; Janko Kos; Anahid Jewett
Journal:  Oncotarget       Date:  2015-09-08

Review 8.  CTSC and Papillon-Lefèvre syndrome: detection of recurrent mutations in Hungarian patients, a review of published variants and database update.

Authors:  Nikoletta Nagy; Péter Vályi; Zsanett Csoma; Adrienn Sulák; Kornélia Tripolszki; Katalin Farkas; Ekaterine Paschali; Ferenc Papp; Lola Tóth; Beáta Fábos; Lajos Kemény; Katalin Nagy; Márta Széll
Journal:  Mol Genet Genomic Med       Date:  2014-02-11       Impact factor: 2.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.